Evidence map›Paper›PMID 32596235›Full record

ArticleFrontiers in cell and developmental biology2020

Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients.

Esben Iversen, Morten Baltzer Houlind, Thomas Kallemose, Line Jee Hartmann Rasmussen, Mads Hornum, Bo Feldt-Rasmussen, Salim S Hayek, Ove Andersen, Jesper Eugen-Olsen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Esben IversenDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Morten Baltzer HoulindDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Thomas KallemoseDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Line Jee Hartmann RasmussenDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Mads HornumDepartment of Nephrology, Rigshospitalet, Copenhagen, Denmark.
Bo Feldt-RasmussenDepartment of Nephrology, Rigshospitalet, Copenhagen, Denmark.
Salim S HayekDepartment of Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, United States.
Ove AndersenDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Jesper Eugen-OlsenDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Hvidovre Hospital · DKUniversity of Copenhagen · DKCopenhagen University Hospital · DKDuke University · USIcahn School of Medicine at Mount Sinai · USRigshospitalet · DKUniversity of Michigan–Ann Arbor · US

Funding

Role of SuPAR in the Intersection between Cardiovascular and Kidney DiseaseR01HL153384 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAYEK, SALIM · 2020 to 2024
$2.5M
NHLBI NIH HHS R01 HL153384
6 · The paper itself

Abstract

introductionIdentifying patients at high risk of developing kidney disease could lead to early clinical interventions that prevent or slow disease progression. Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker thought to be involved in the pathogenesis and development of kidney disease. We aimed to determine whether elevated plasma suPAR measured at hospital admission is associated with incident kidney disease in patients presenting to the emergency department. MATERIALS AND

methodsThis was a retrospective registry-based cohort study performed at the Emergency Department of Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. Patients were included in the study from November 2013 to March 2017 and followed until June 2017. Patients were excluded if they were diagnosed with kidney disease or died prior to index discharge. Plasma suPAR was measured at hospital admission, and the main outcome was time to incident kidney disease, defined by ICD-10 diagnosis codes for both chronic and acute kidney conditions. Association between suPAR and time to incident kidney disease was assessed by Cox proportional hazard regression analysis.

resultsIn total, 25,497 patients (median age 58.1 years; 52.5% female) were admitted to the emergency department and followed for development of kidney disease. In multivariable Cox regression analysis adjusting for age, sex, eGFR, CRP, cardiovascular disease, hypertension, and diabetes, each doubling in suPAR at hospital admission was associated with a hazard ratio of 1.57 (95% CI: 1.38-1.78, DISCUSSION: In a large cohort of acutely hospitalized medical patients, elevated suPAR was independently associated with incident chronic and acute kidney conditions. This highlights the potential for using suPAR in risk classification models to identify high-risk patients who could benefit from early clinical interventions. The main limitation of this study is its reliance on accurate reporting of ICD-10 codes for kidney disease.

Indexed as

acute kidney injurychronic kidney diseasedialysisemergency departmentglomerular filtration ratesoluble urokinase plasminogen activator receptor

Identifiers

PMID32596235
PMCPMC7303513
OpenAlexW3034768144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.